Gemtuzumab Ozogamicin in children with relapsed or refractory acute myeloid leukemia
Standard
Gemtuzumab Ozogamicin in children with relapsed or refractory acute myeloid leukemia : a report by Berlin-Frankfurt-Münster study group. / Niktoreh, Naghmeh; Lerius, Beate; Zimmermann, Martin; Gruhn, Bernd; Escherich, Gabriele; Bourquin, Jean-Pierre; Dworzak, Michael; Sramkova, Lucie; Rossig, Claudia; Creutzig, Ursula; Reinhardt, Dirk; Rasche, Mareike.
in: HAEMATOLOGICA, Jahrgang 104, Nr. 1, 01.2019, S. 120-127.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Gemtuzumab Ozogamicin in children with relapsed or refractory acute myeloid leukemia
T2 - a report by Berlin-Frankfurt-Münster study group
AU - Niktoreh, Naghmeh
AU - Lerius, Beate
AU - Zimmermann, Martin
AU - Gruhn, Bernd
AU - Escherich, Gabriele
AU - Bourquin, Jean-Pierre
AU - Dworzak, Michael
AU - Sramkova, Lucie
AU - Rossig, Claudia
AU - Creutzig, Ursula
AU - Reinhardt, Dirk
AU - Rasche, Mareike
N1 - Copyright© 2019 Ferrata Storti Foundation.
PY - 2019/1
Y1 - 2019/1
N2 - Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia (AML) have poor survival. We evaluated gemtuzumab ozogamicin (CD33-targeted drug) used on a compassionate basis in patients diagnosed from 1995 until 2014 within Acute Myeloid Leukemia Berlin-Frankfurt-Münster studies, and identified 76 patients (<18 years) with highly-advanced and pre-treated AML [refractory de novo acute myeloid leukemia (n=10), de novo AML refractory to relapse (1st early: n=41; 1st late: n=10; 2nd or more: n=10), and secondary AML (n=5)]. At doses of 2.5-10 mg/m2, gemtuzumab ozogamicin was administered in 1-4 cycles as single agent (47%), combined with cytarabine (47%), or others (6%). Most common grade 3/4 adverse events were infections or febrile neutropenia (78% of severe adverse events), infusion-related immunological reactions (6%), and gastrointestinal symptoms (5%). Three patients experienced veno-occlusive disease (one fatal due to exacerbation of a pre-existing cardiomyopathy). Sixty-four percent received subsequent hematopoietic stem cell transplantation. Probability of 4-year overall survival was 18±5% in all, 27±7% in patients with and 0% in patients without hematopoietic stem cell transplantation (P<0.0001). Administration of gemtuzumab ozogamicin on a patient-specific, compassionate use basis was frequently considered in our study group and proved to be effective for bridging children with very advanced AML to hematopoietic stem cell transplantation. Uniform prospective studies for these patients are urgently needed.
AB - Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia (AML) have poor survival. We evaluated gemtuzumab ozogamicin (CD33-targeted drug) used on a compassionate basis in patients diagnosed from 1995 until 2014 within Acute Myeloid Leukemia Berlin-Frankfurt-Münster studies, and identified 76 patients (<18 years) with highly-advanced and pre-treated AML [refractory de novo acute myeloid leukemia (n=10), de novo AML refractory to relapse (1st early: n=41; 1st late: n=10; 2nd or more: n=10), and secondary AML (n=5)]. At doses of 2.5-10 mg/m2, gemtuzumab ozogamicin was administered in 1-4 cycles as single agent (47%), combined with cytarabine (47%), or others (6%). Most common grade 3/4 adverse events were infections or febrile neutropenia (78% of severe adverse events), infusion-related immunological reactions (6%), and gastrointestinal symptoms (5%). Three patients experienced veno-occlusive disease (one fatal due to exacerbation of a pre-existing cardiomyopathy). Sixty-four percent received subsequent hematopoietic stem cell transplantation. Probability of 4-year overall survival was 18±5% in all, 27±7% in patients with and 0% in patients without hematopoietic stem cell transplantation (P<0.0001). Administration of gemtuzumab ozogamicin on a patient-specific, compassionate use basis was frequently considered in our study group and proved to be effective for bridging children with very advanced AML to hematopoietic stem cell transplantation. Uniform prospective studies for these patients are urgently needed.
KW - Journal Article
U2 - 10.3324/haematol.2018.191841
DO - 10.3324/haematol.2018.191841
M3 - SCORING: Journal article
C2 - 30093401
VL - 104
SP - 120
EP - 127
JO - HAEMATOLOGICA
JF - HAEMATOLOGICA
SN - 0390-6078
IS - 1
ER -